Ozempic Alternative May Offer Weight Loss Without Injections or Muscle Loss
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A new weight loss pill currently undergoing clinical trials could help burn fat and lower blood sugar levels like Ozempic and similar GLP-1 agonists, but without muscles loss as a potential side-effect.
This is the conclusion of a new study by an international team of researchers led from the biotech firm Atrogi AB.
"This drug represents a completely new type of treatment and has the potential to be of great importance for patients with type 2 diabetes and obesity," said paper author professor Shane Wright of the Karolinska Institutet in a statement.
"Our substance appears to promote health aging weight loss—and, in addition, patients do not have to take injections."
Stock image of weight loss pills.
Stock image of weight loss pills.
celsopupo/iStock / Getty Images Plus
GLP-1 agonists like Ozempic work, in part, by altering gut-brain signals to decrease hunger; however, their side effects can include a loss in muscle mass.
The new drug, in contrast, is a type of so-called "β2 agonist" which works by activating signaling pathways in the body in such a way that has a positive effect on muscles. Unlike existing β2 agonists, however, it does not have the drawback of overstimulating the heart.
In mice models of diabetes and rat models of obesity, the drug has demonstrated benefits for both body composition and blood sugar control.
"Our results point to a future where we can improve metabolic health without losing muscle mass," said paper co-author and Stockholm University molecular biologist professor Tore Bengtsson in a statement.
"Muscles are important in both type 2 diabetes and obesity—and muscle mass is also directly correlated with life expectancy."
While the effectiveness of the new treatment has yet to be evaluated in humans, a phase I clinical trial (which involved 48 healthy subjects and 25 people with type 2 diabetes) has shown that the drug is well-tolerated in humans.
A further advantage of the new drug, the team explained, is that because it has a different mechanism of action to Ozempic and other GLP-1 agonists, they could be taken together.
"This makes them valuable both as a stand-alone treatment and in combination with GLP-1 drugs," explained Wright.
With this initial study complete, researchers are now looking to undertake a larger clinical study to see if the drug offers the same benefits to humans with type 2 diabetes or obesity as it did in the mice models of these conditions.
Do you have a tip on a health story that Newsweek should be covering? Do you have a question about weight loss medication? Let us know via health@newsweek.com.
Reference
Motso, A., Pelcman, B., Kalinovich, A., Kahlous, N. A., Bokhari, M. H., Dehvari, N., Halleskog, C., Waara, E., de Jong, J., Cheesman, E., Kallenberg, C., Yakala, G. K., Murad, P., Wetterdal, E., Andersson, P., van Beek, S., Sandström, A., Alleluia, D. N., Talamonti, E., Youhanna, S., Sabatier, P., Koenig, C., Willems, S., Kemas, A. M., Hutchinson, D. S., Ham, S., Grätz, L., Voss, J., Marchan-Alvarez, J. G., Priede, M., Jaunsleine, K., Spura, J., Kovada, V., Supe, L., Stoddart, L. A., Holliday, N. D., Newton, P. T., Pillon, N. J., Schulte, G., Summers, R. J., Mutule, I., Suna, E., Olsen, J. V., Molenaar, P., Carlsson, J., Lauschke, V. M., Wright, S. C., & Bengtsson, T. (2025). GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity. Cell. https://doi.org/10.1016/j.cell.2025.05.042
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
an hour ago
- Newsweek
California Schools to Change From August: What to Know
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. California schools are set to implement a number of changes in the upcoming school year starting August. Schools will be required to print suicide prevention resources on student identification cards, and start planning for the future of students with special needs as soon as they enter high school. Newsweek contacted California Governor Gavin Newsom's office and the California Department of Education for comment via email outside of regular working hours. Governor Gavin Newsom speaking in California in April. Newsom has championed improving access to mental health services for students in the state. Governor Gavin Newsom speaking in California in April. Newsom has championed improving access to mental health services for students in the state. Noah Berger/AP Why It Matters The measures are part of a legislative agenda championed by Newsom to improve access to mental health services for students, and to support students with special needs. What To Know Under Senate Bill 1063, public or private schools that serve students in grades seven to 12 and issue identification cards will be required to print the number for the 988 Suicide and Crisis Lifeline on students' IDs. This is a change from a previous requirement to have the number for the National Suicide Prevention Lifeline printed on ID cards, according to the bill. The 988 Suicide & Crisis Lifeline's three-digit number, which launched in 2022, replaced the National Suicide Prevention Line's 10-digit number, even though that still remains active. The law also allows schools to print a QR code on ID cards linking to the mental health resources website of the county in which the school is located. Assembly Bill 438, which was approved last year, requires that individualized education programs, or IEPs, include measurable post-secondary goals and transition services for students with special needs from as early as when they start high school, if determined appropriate by the IEP team. The change will mean that planning for the student's post-secondary goals could begin up to two years earlier than previously, according to Newsom's office. What People Are Saying California State Senator Shannon Grove, a Republican who authored Senate Bill 1063, said in a statement last year: "Updating student ID cards so children have immediate access to mental health resources is smart policy... I am thrilled that students across the state of California will now have essential mental health resources at their fingertips to combat their distress." The California Department of Education said in a statement in May: "As explained in AB 438, existing law requires IEPs to include appropriate measurable postsecondary goals and transition services, as defined, beginning not later than the first IEP to be in effect when a pupil is 16 years old, or younger if determined appropriate by the IEP team, which are to be updated annually. "Beginning July 1, 2025, AB 438 requires an IEP to include measurable postsecondary goals and transition services, if determined appropriate by a pupil's IEP team, beginning when an individual with exceptional needs starts their high school experience and not later than the first IEP to be in effect when the pupil is 16 years of age." What Happens Next The two laws go into effect on July 1, 2025, and will impact students from the start of the school year beginning in August.
Yahoo
2 hours ago
- Yahoo
Diabetic patients taking GLP-1s may face increased risk of eye disease, study suggests
Diabetes is the leading cause of vision loss in people between 18 and 64 years old, according to the American Diabetes Association — and the best way to prevent this is to control blood sugar levels. Glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic and Mounjaro, have become popular medications for controlling diabetes and treating obesity — but new Canadian research suggests they can also lead to a paradoxical side effect in the form of eye problems. Young Police Officer Dies By Suicide After 'Debilitating' Laser Eye Surgery Complications A retrospective study conducted from January 2020 to November 2023 included more than 139,000 diabetic patients, some of whom were taking GLP-1s for at least six months and some who were not taking the medications over a three-year period. The average age of the participants was 66 years old, and approximately 47% were women. Researchers found that the participants taking the weight-loss medications had twice the risk of developing neovascular age-related macular degeneration (nAMD) compared to the people not taking them. Read On The Fox News App "There have been growing reports of [eye] adverse events with GLP-1 receptor agonists, but no clear consensus regarding their impact on age-related macular degeneration (AMD) progression," study author Dr. Rajeev Muni, an ophthalmologist and vice-chair of clinical research in the Department of Ophthalmology and Vision Sciences at the University of Toronto, told Fox News Digital. 6 Simple Ways To Protect Your Hearing Now Before It's Too Late, According To Experts "In particular, we observed a dose-response relationship — the longer patients were exposed to these medications, the greater their risk appeared to be," added author Reut Shor, a researcher in the department of ophthalmology and vision sciences at the University of Toronto. The findings were published in the journal JAMA Ophthalmology. Age-related macular degeneration (AMD) is the most common cause of vision loss in those aged 50 and older in the developing world, according to the American Society of Retinal Specialists. Approximately 20 million adults in the U.S. have the condition. It mainly affects people's central vision, which means they have a challenging time seeing in front of them, but their peripheral vision is intact, according to the National Institutes of Health (NIH). There are two types of AMD – dry and wet. Dry AMD, the most common type, occurs when small yellow deposits of protein develop under the macula, but symptoms may not occur in the early stages, experts said. In about two out of every 10 cases, dry AMD develops into wet AMD — also known as neovascular age-related macular degeneration (nAMD). With this more advanced type of disease, abnormal blood vessels form under the retina and start to leak, causing damage to the central part of the retina, known as the macula, according to WebMD. "When this occurs, symptoms include loss of central vision, distortions in vision and blank areas missing in the central vision," Nishika Reddy, M.D., assistant professor of ophthalmology at Moran Eye Center's Midvalley Health Center at the University of Utah, told Fox News Digital. (She was not part of the study.) Risk factors for nAMD include chronic heart failure, chronic kidney disease and diabetes – all of which often overlap with those who take GLP-1s, experts confirmed. The study authors cautioned that their findings should be taken in the context of the overall higher risk of eye disease in older people. The incidence of nAMD in the general population is about one in 1,000, and it doubled to two in 1,000 for the group taking the GLP-1s in the study. However, the overall absolute risk is still small, according to the researchers. The study's main limitation is that it was observational in nature, meaning the researchers could not confirm that GLP-1s medications cause neovascular age-related macular degeneration. The study also could not draw conclusions about younger populations, the researchers acknowledged. "Also, our findings apply only to diabetic patients aged 66 years or older, and cannot be directly generalized to non-diabetic individuals using GLP-1 receptor agonists for weight loss," Shor told Fox News Digital. GLP-1 receptors are present in the retina regardless of age or diabetes status — so theoretically, the risk could apply to younger populations. More research is needed to better understand why diabetic people on GLP-1s have increased eye disease, Shor said. Click Here To Sign Up For Our Health Newsletter "While the risk of developing macular degeneration while on a GLP-1 drug is low, patients should be aware of the possible eye side effects related to these types of medications," Reddy said. If someone notices blurred or distorted vision, straight lines appearing wavy, or any new blind spots, they should seek medical attention, according to Muni. For more Health articles, visit Early detection of eye disease is crucial, experts agree, as timely treatment can reduce the risk of vision loss. The study authors said they hope their findings will empower patients to monitor for early article source: Diabetic patients taking GLP-1s may face increased risk of eye disease, study suggests
Newsweek
2 hours ago
- Newsweek
Woman Screams As Snake Attacks—Dog Jumps In and Takes the Venom for Her
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A Border collie has been dubbed a hero after he protected his owner from a venomous rattlesnake—earning praise from people all over the world. The 8-year-old canine, named Dog, lives in Killeen, Texas, with his owner. She let out a scream when she encountered a juvenile Western diamondback rattlesnake while pulling weeds outside her home. Her niece, Chloe Palousek, 28, told Newsweek that the frightening moment took a dramatic turn when the snake reared its head—and Dog sprang into protector mode. "She saw it raise its head and screamed," Palousek said. "Dog, who was already outside, ran over to her and picked up the snake … It bit his lip." From left: Dog the Border collie rests at home. From left: Dog the Border collie rests at home. cashmoneychloe/Reddit The Western Diamondback Rattlesnake is native to the southwestern United States and northern Mexico and carries a dangerous venom that destroys blood cells and tissue, causes pain and swelling, and can impair blood clotting. One of the most frequently responsible species for snakebites in the U.S., the rattlesnake's bites can be deadly if left untreated, especially for children and the elderly. Dog was immediately rushed to the vet, where he received antivenin and spent the night under observation. Despite the painful encounter, thankfully he made a swift recovery. "His doctor said he was doing amazing," Palousek said. "He's on antibiotics, steroids, and pain meds, but he's doing a lot better. The swelling from the bite only lasted about three days." Palousek shared Dog's heroic actions on Reddit where the post has gained over 4,000 upvotes and more than 400 comments. The reactions flooded Dog with well wishes and admiration. "What a good boy! I sure hope he makes it though this with no lasting issues," said one commenter. Another wrote: "Poor baby. I love this breed. They truly love and protect their humans. They are so beautiful on the inside and out." "Give that bestest boy a steak," posted a third. One comment added: "Oh my god I cried when I saw this. I'm glad he's going home. Best doggy gets all the love. Give him kisses for me!!" Palousek was delighted by the reaction online: "The reaction from Reddit has been wonderful, and full of support and kind words. He has a huge support system, and we are very grateful," she said. Dog isn't the first pet to have a face-to-face encounter with a snake. Last year, another canine learned the hard way that "snakes are friends, not food," when he was bitten by a rattlesnake. Do you have funny and adorable videos or pictures of your pet you want to share? Send them to life@ with some details about your best friend, and they could appear in our Pet of the Week lineup.
